Company Overview
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -92.03% |
| 6 Months: | -74.19% |
| 3 Months: | -10.04% |
| 1 Month: | -56.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.23 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TVGN Tevogen Bio Holdings Inc. R2K | 5.02 | -0.78 | $21.02M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | - | - | -2.32M | -2.18M | -2.33M | -29.52M | -8.60M | -6.09M | -10.36M | -5.44M | -5.73M | -5.40M |
| Net Income | -11.30K | -115 | -25.99K | 207.00K | 1.61M | -30.76M | -22.18M | -3.90M | 11.26M | -9.66M | -5.88M | -10.37M | -5.50M | -5.73M | -5.45M |
| Diluted EPS | - | - | 0.00 | - | - | -0.26 | -0.18 | -0.03 | -0.26 | -0.04 | -0.03 | -3.25 | -0.03 | -0.03 | -1.61 |
| R&D Expense | - | - | - | - | - | 1.35M | 1.03M | 1.12M | 20.81M | 4.12M | 3.26M | 3.20M | 2.70M | 3.11M | 3.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | - | -8.84M | -53.56M | -26.14M |
| Net Income | 4.41M | -60.48M | -13.73M | -26.28M |
| Diluted EPS | - | -2.44 | -3.50 | -8.08 |
| R&D Expense | - | 4.40M | 31.03M | 11.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 352.85M | 357.14M | 5.51M | 3.46M | 4.38M |
| Total Equity | 0 | -14.23M | -33.95M | -94.43M | -6.67M | -8.23M |
| Cash & Equivalents | - | 344.58K | 129.19K | 0 | 0 | 0 |
| Total Liabilities | - | 15.18M | 15.06M | 99.93M | 10.14M | 12.62M |
| Current Liabilities | - | 59.38K | 350.45K | 85.48M | 9.04M | 7.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -215.40K | -8.17M | -12.00M | -12.33M |
| Investing Cash Flow | - | -133.00K | - | -64.44K |
| Financing Cash Flow | - | 3.87M | 12.23M | 11.66M |
| Capital Expenditure | - | -133.00K | - | -64.44K |
| Free Cash Flow | - | -8.30M | - | -12.39M |
| Share Buybacks | - | 342.98M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -13.0% | 64.0% | 205.7% | 319.1% |
| ROCE % | - | 11.1% | 959.8% | 973.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 0.79% | 33.25K | $195.16K |
| 2 | Blackrock Inc. | 0.58% | 24.39K | $143.20K |
| 3 | Morgan Stanley | 0.41% | 17.33K | $101.75K |
| 4 | Geode Capital Management, LLC | 0.37% | 15.73K | $92.36K |
| 5 | Deutsche Bank AG | 0.36% | 15.32K | $89.95K |
| 6 | FMR, LLC | 0.24% | 10.16K | $59.62K |
| 7 | Russell Investments Group, Ltd. | 0.14% | 5.81K | $34.08K |
| 8 | Vanguard Portfolio Management LLC | 0.11% | 4.53K | $26.56K |
| 9 | UBS Group AG | 0.08% | 3.57K | $20.94K |
| 10 | Vanguard Fiduciary Trust Co | 0.03% | 1.37K | $8.03K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TVGN
Dr. Saadi boosts control at Tevogen Bio Holdings (TVGN) with stock grant - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNSXBldi11bmt1ZHgwUFhjVlAzbXRob1NOSlQ1MGxFQktqc3BXLVVmQzE0eFZXUFlWVWJ4Y1kzVnNaa1FFTzMzdGJ5bnpiaC1DS2JSb1RkZGxEb1pYZXp5amF4ajJIRkpoc19UVG9PWlhZQUNnOVNMZUJ4djNKZlNVQ0tJQXVmUjJwLUhtej…
Tevogen Bio Holdings(TVGN) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiiANBVV95cUxPd1NVZ3BQZFppNnlxVWJMdWJKajJNOUNGSkR2YUJKUEROaUZDN1hTYXFjZGtiMUNiTkhhTUhVNkIyNlAxWWh5bmRMSl82NmdibmpPTTR3bjhlbjNaYjUzaUwyVjJzanhHR2dKLTZWVW1CdVFlMVJ1QjFaWTNuNVJpN0FuVF9WNy1EZ2g1RG…
Tevogen stockholders face a July 23 deadline to submit proposals - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPRHpuYkFXOXlzbHhmT0RWLVNSVFRId0JPQ19ISm1PT3BZQ2F2Z0R3UmRybU9WMFZ6dFpsSTA4QVRpSE1FR3I2ODc0MkpkTmdzcElRMjFNMjVrdnlPRkEyLXpTQVNqRU9nRXJwS29acDFtNmpzRWRPeGxPNE9iUktyeE9ud1MzRzZLdlVQTF…
Form 13D/A Tevogen Bio Holdings Inc. For: 14 July By Investing.com - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNWlZGblRnb1pyM01qMWlJak41TFVfbC1tb3Q1WDUwWXEyU09YYnBCTDg3ZWdLUmRUYTl6RmZDZlRHN2tIOFJsNVEwaWNIU3V1cW9KVlV3NmJaazh2OXRWYWJDLTlhRWZySFFTVWRnazB3TVI2MXhVWXR3cENrcTA5S3RpdUtTb1NxeVBkd0…
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZjA4ZXZVa3RRVlI5bWM5SkdVaWdCMndpX3JiUk1tb1lqQ2I0WXJ0MC1WaVFfLS1XSmc1VF9CMHhhZWkzUURpWldObHV0cktnMEV3bGNyYTFFZWVIdkk5MnlMOXRlUC1Eei1fN1pTZUxDTnVFV0Y5cWlTVm9TNHhkWmg5V0sza2pMN3NJ?o…
Tevogen Bio (TVGN) Stock Pre-Market (-4.1%): New Diversified Strategy Met With Skepticism - Trefis
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNWkZ0UmtLMVliaGk0RW5QcWk3YUZ2WXJtRFZEeVEtQjJXOHR5ZmdMSVVBSktWXzlPVWpGak9JWG5uV3RvUUZPT1oyNnRra2dWd2hsU1JYYzkxVC13MHg2VFFZT2ZaekFGYmlabHQ4Ty0tZE53bUUtU2gxZFJ2UXZvYUNVTW5KQ1BDclJxdE…
TVGN — Frequently Asked Questions
What is the current share price of Tevogen Bio Holdings Inc. (TVGN)?
As of 2026-07-14 21:23 PDT, Tevogen Bio Holdings Inc. (TVGN) trades at $5.02 on NasdaqGM. Its 52-week range is $4.29 to $63.00.
What is the market capitalisation of TVGN?
Tevogen Bio Holdings Inc. (TVGN) has a market capitalisation of $21.02M on NasdaqGM.
What is the P/E ratio of TVGN?
TVGN trades at a trailing price-to-earnings (P/E) ratio of -0.78. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -2.47.
Is TVGN a good stock to buy?
This page provides a data-driven analysis of Tevogen Bio Holdings Inc. (TVGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.